Zhaoguang Wang

Area of research

Pulmonary and Respiratory Medicine · Oncology

Research interest

Research focused on Oncology and Pemetrexed, with related work in Apatinib, Carboplatin, Trastuzumab. Notable publications include 'Consensus for HER2 alterations testing in non-small-cell lung cancer', 'Phase III Study of Apatinib in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial', and 'LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)'.

1323P RATIONALE-307 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC

Annals of Oncology 2024cited by 1position: firstdoi

OA01.03 Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial

Journal of Thoracic Oncology 2023cited by 12position: middledoi

Consensus for HER2 alterations testing in non-small-cell lung cancer

ESMO Open 2022cited by 108position: middledoi

4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

Annals of Oncology 2022cited by 6position: middledoi

MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

Journal of Thoracic Oncology 2021cited by 11position: middledoi

P83.03 Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation

Journal of Thoracic Oncology 2021cited by 3position: middledoi

LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)

Annals of Oncology 2020cited by 17position: middledoi

1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC

Annals of Oncology 2020cited by 10position: middledoi

ID:1329 ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology 2020cited by 4position: middledoi

LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)

Annals of Oncology 2020cited by 2position: middledoi

Phase III Study of Apatinib in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Annals of Oncology 2014cited by 21position: middledoi

Recent publications

Grants

Frequent collaborators